Portfolio expansion TSCP actively acquires and builds portfolio companies across Life Sciences, Software, and Services sectors, indicating potential cross-sell and growth opportunities for operating partners, portfolio expansions, and strategic add-on acquisitions.

Recent M&A activity Freddy’s acquisition by Rhône Group from TSCP and multiple 2024–2026 actions suggest TSCP is actively reshaping its holdings, presenting opportunities to engage on exit strategies, seller readiness, or advisory roles for future dispositions.

New platforms Launch of Complex Claims Recovery and ongoing ownership of portfolio companies such as BuildClinical and Pest Control businesses indicate potential demand for B2B software, clinical trial recruitment, or field services technology enhancements to improve operations and outcomes.

Industry reach Diversified sector focus from Life Sciences and Healthcare to Software and Consumer Services signals cross-industry collaboration opportunities, including cross-portfolio partnerships, co-investments, and scalable tech-enabled solutions.

Financial scale Reported revenue range places TSCP as a mid-market PE player with substantial deal flow; outreach could emphasize offering growth capital, add-on acquisition financing, or specialized consulting to accelerate portfolio company value creation.